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Abstract 
Background: Since the number of drug users is increasing, applying a method of detoxification with 
fewer side effects during withdrawal from opioids and greater reliability seems to be necessary. In 
addition, without maintenance treatment, there will be limited success of treatment. This study aimed 
to compare success rates of detoxification with sublingual buprenorphine and clonidine and to 
evaluate addiction relapse in patients using naltrexone in a six-month follow-up. 
Methods: This double-blind trial was carried out on opioid dependent patients in a psychiatric hospital 
in Kerman (Iran) during 2007-09. The subjects were randomly selected from individuals who had 
referred for detoxification. They were allocated to two groups to receive either clonidine (n = 21) or 
buprenorphine (n = 14). The success rates of the two methods were assessed at the end of the course 
and patients were discharged while prescribed with 25 mg daily use of naltrexone. They were followed 
up for six months and the continuous use of naltrexone and relapse of substance abuse were evaluated. 
Findings: A total number of 35 patients entered the study. Success of detoxification with naltrexone 
was confirmed in all cases. One person (8.4%) in the clonidine group and no patient in the 
buprenorphine group had a clinical opiate withdrawal scale (COWS) score of more than 12  
(P > 0.05). The mean levels of objective signs and subjective symptoms of withdrawal and the desire 
for drug abuse had significant reductions during detoxification period in both groups (P < 0.001). 
However, the difference in these variables between the two groups was not statistically significant  
(P > 0.05). Naltrexone was used for an average of one month in 43% and 64% of subjects in the 
clonidine and buprenorphine groups, respectively. In addition, 62% of patients in the clonidine group 
and 92.8% of subjects in the buprenorphine group received maintenance treatment. Nevertheless, the 
mean number of days staying in treatment was not significantly difference between the two groups  
(P > 0.05). 
Conclusion: Buprenorphine is as effective as clonidine in controlling withdrawal symptoms. A greater 
percentage of patients detoxified by buprenorphine received maintenance treatment, but there was not 
a significant difference in relapse rates between the two methods. 
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Introduction  
Drug dependence, a psychiatric disorder with 
biological, psychological and social dimensions, 
is considered as a major problem in Iran. The 
prevalence of drug dependence among human 
societies has increased clearly.1,2 Since medical 
issues, mental illness of companions, and other 
related factors such as family breakdown, 
unemployment, and legal issues are all of high 
prevalence among drug addicts, these 
individuals are a serious problem for the 
Iranian Department of Health and other social 
services in the country.2 A previous study 
reported that 74.4% of patients who referred to 
an addiction treatment clinic used opium and 
20.8% used heroin.3 
Effective control of drug withdrawal 
symptoms and helping patients to tolerate the 
withdrawal stage are essential in attempts to 
quit drug abuse and to prevent its 
consequences such as relapse.4,5 Withdrawal 
syndrome includes subjective symptoms and 
objective signs which begin within 6-8 hours 
after taking substances in drug dependent 
patients. Among the many available methods to 
control these symptoms is using alpha-
adrenergic agonists like clonidine and 
guanfacine that prevent the occurrence of 
noradrenergic withdrawal syndrome.6 Success 
rate of this method has been reported as  
10-90%.7,8 Opioid agonists such as methadone 
are also a standard method of withdrawal from 
opioids in many countries.5,9,10 However, the 
use of methadone has some limitations due to 
its side effects risk of death when used 
excessively and uncontrolled.2,11  
The efficacy of buprenorphine in controlling 
the symptoms of withdrawal syndrome has been 
recently evaluated.4,11 Buprenorphine is a partial 
agonist with high affinity and low intrinsic 
activity at mu receptors and antagonist activity 
at kappa receptors. It is safer than methadone 
since it does not slow down breathing and has 
less autonomous withdrawal symptoms, and 
reduced psychomimetic effects or dysphoria.12  
Similar to methadone, overuse of 
buprenorphine is dangerous. Therefore, a 
combination of buprenorphine and naloxone 
(called Suboxone) has been introduced and 
confirmed by the US Food and Drug 
Administration (FDA)13,14 to reduce the risk of 
excessive intravenous injection by the naloxone 
component.2,11 
Different drug regimens, impurities of 
substances used in each country, different 
drug metabolism of people, and different races 
are all effective in detoxification. Since there 
are inconsistencies in the findings of previous 
studies, the present study compared the 
success of sublingual buprenorphine 
prescription in controlling opium withdrawal 
syndrome with clonidine and evaluated 
relapse rate during a six-month period of 
naltrexone maintenance treatment. 
 
Methods 
This double-blind clinical trial was conducted 
on male opioid-dependent patients seeking for 
detoxification in Shahid Beheshti Hospital 
(Kerman, South East Iran) during 2007-09. 
Subjects were diagnosed as opioid-dependent 
according to the Fourth Diagnostic and 
Statistical Manual of Mental Disorders  
(DSM-IV).15 They aged 18-40 years old and 
were visiting for detoxification for the first time. 
In addition, they were able to read and write. 
Exclusion criteria were serious medical 
conditions such as acute hepatitis, liver disease 
(serum glutamic oxaloacetic transaminase > 50), 
diabetes, acute psychotic disease and 
personality disorder, concomitant abuse of 
methadone, beta-blockers, or calcium channel 
blockers, any medical condition interfering 
with clonidine such as heart disease, 
cardiovascular disease, and renal disease, and 
finally, a history of allergy to clonidine, 
buprenorphine, or naltrexone. In addition, 
patients with blood pressure below 90/60 
mmHg and a pulse below 60 beats per minute 
during treatment were excluded from the study. 
The study procedure was confirmed by the 
Ethics Committee of the Neuroscience Research 
Center (Kerman, Iran). Afterward, 50 patients 
seeking addiction therapy were evaluated. 
Since 15 subjects were excluded due to 
ineligibility or unwillingness to participate,  
35 subjects were finally included. After being 
thoroughly explained about the study  
and signing a written consent form, the 
participants were randomly allocated to  
either clonidine or buprenorphine 
detoxification group. In the next stage, 
psychiatric interviews, clinical examination, 
and medical history taking were performed by 
a psychiatry resident. Complete blood count 
(CBC) test, kidney and liver function tests, 
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hepatitis and human immunodeficiency virus 
(HIV) tests were also conducted. 
To ensure blinding, the placebo of each drug 
was also prepared by the Department of 
Pharmacology of Kerman University of Medical 
Sciences (Kerman, Iran). Therefore, group 1  
(n = 14) received buprenorphine and clonidine 
placebo and group 2 (n = 21) received clonidine 
and buprenorphine placebo. All drugs and 
placebos were assigned a code and kept by a 
person who was not involved in the study. In 
group 1, 2 mg sublingual tablets of 
buprenorphine hydrochloride were used. On 
days 1-5, one oral clonidine placebo tablet and 
2, 4, 6, 4, and 2 mg/day buprenorphine were 
administered, respectively. In some cases, 
depending on the severity of symptoms, 2-4 mg 
buprenorphine were added in the withdrawal 
phase.14,16,17 In group 2, 0.2 mg oral clonidine 
tablets and sublingual buprenorphine placebo 
tablets were administered. They received one 
tablet twice on the first day, one tablet three 
times daily on the second and third days, and 
one tablet daily on the fourth and fifth days. 
Moreover, 0.2-0.4 mg/day additional drug was 
administered if indicated.5,18,19 Vital signs of 
patients were controlled four times a day and 
before administration of each drug dose. 
Patients were also evaluated for appearance of 
side effects by a physician and a nurse 
according to various references. Urine test for 
opioid substance was performed using thin 
layer chromatography.  
The main outcomes investigated in this 
study included the clinical opiate withdrawal 
scale (COWS) score above 12 on day 5, the 
success rate of detoxification with naltrexone 
two days after the end of detoxification phase, 
the rate of remaining in treatment with 
naltrexone in a six-month monitoring period, 
and also the rate of positive urinary samples for 
opioids at the end of six months. The intensity 
of signs and symptoms of withdrawal in the 
detoxification phase and the desire for 
substance abuse were also evaluated in these 
patients. In order to assess the intensity of 
signs, the COWS was applied. It consists of 11 
items (scored as 0-4 or 0-5). A total of 5-12 
points indicates weak withdrawal signs, 13-24 
stand for moderate withdrawal signs, 25-36 
show moderate to severe withdrawal signs, and 
points above 36 demonstrate severe withdrawal 
signs.20,21 The COWS was filled out by a 
psychiatric technician at 9 a.m. on days 1, 2, 3, 
and 5. The intensity of psychiatric withdrawal 
signs was evaluated using the Adjective Rating 
Withdrawal Scale (ARWS) which consists of 16 
items rated as 0-9 by the patient.22 The desire 
for substance abuse was assessed using a visual 
analogue scale (VAS) in which a 10 cm line was 
marked by the patient to indicate his desire for 
substance abuse.23  
To ensure the success of detoxification, 
patients received naltrexone two days 
following detoxification. They were then 
discharged while prescribed with 25 mg/day 
naltrexone for six months. They were 
monitored every two months by questioning 
the patient and his family on the phone about 
continuing the use of naltrexone and 
maintaining the treatment. In cases of 
contradiction between the statements of 
patients and their families, the family was 
considered to be the main reference. Since the 
validity and accuracy of self-proclaimed 
statements depend on the confidentiality of 
information, data should be collected in a safe 
place within acceptable limits.24 Previous studies 
have indicated the accuracy of self-proclaimed 
data in Iran.25 Monitoring was completed at the 
sixth month through obtaining urine tests. 
Withdrawal symptoms were controlled with 
trazodone, lorazepam, hydroxyzine, 
acetaminophen, and hyoscine as required. 
Chi-square test, Fisher's exact test, and 
t-test were used to compare nominal and 
numerical variables. The mean days of stay in 
treatment were determined by Kaplan-Meier 
test and compared between the two groups by 
log-rank test. All data analyses were 
performed with SPSS for Windows 17.0 (SPSS 
Inc., Chicago, IL, USA). P values less than 0.05 
were considered significant. 
 
Results 
The mean age of subjects in the clonidine and 
buprenorphine groups were 25.1 ± 1.6 and  
25.7 ± 1.2 years, respectively (P > 0.05). The 
mean amount of substance-taking was 3.4 ± 0.2 
mg in clonidine group and 3.4 ± 0.3 mg in the 
buprenorphine group (P > 0.05). In the 
clonidine group, 71.4% of the subjects were 
employed, 33.3% were married, and only 8.4% 
had university education. In the buprenorphine 
group, 42.9% of patients were employed, 35.7% 
were married, and 14.3% had university 
education (P > 0.05).  
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Changes in the mean scores of COWS and 
ARWS and desire for substance abuse (craving) 
are presented in table 1. One subject (4.8%) in 
the clonidine group and none in the 
buprenorphine group had a COWS score above 
12 on day 5 (P > 0.05). 
The mean number of days remaining in 
treatment and the mean number of days 
receiving naltrexone in the two groups are 
presented in table 2. Frequency of naltrexone 
use and the number of people who remained in 
treatment in the two groups are shown in  
tables 3 and 4. 
According to personal and family 
statements and with confirmation of urine test, 
two patients maintained withdrawal in the six-
month monitoring after detoxification and 
discharge. In the buprenorphine group, three 
subjects completed the treatment. Since none of 
the subjects referred for urine test, the 
statements of families could not be confirmed. 
All patients took naltrexone at the end of the 
detoxification period. In one case, clonidine was 
discontinued on the second day due to blood 
pressure below 90/60 mmHg. Moreover, one 
patient in the clonidine group complained of 
dysphoria. 
 
Discussion 
Although many cases faced an increased 
severity of withdrawal symptoms after the last 
period of use, the symptoms were mild and 
moderate and were eliminated after 48-72 hours 
after taking the medicine.  
This investigation showed that 
administration of buprenorphine for a few days 
can be as effective as clonidine in controlling 
the signs and symptoms of opioids withdrawal. 
In fact, comparing the effectiveness of these two 
drug groups in terms of detoxification did not 
show statistically significant differences. In 
contrast, Gowing et al. reviewed 22 studies on a 
total number of 1763 people and found that 
buprenorphine was more effective than 
clonidine or lofexidine in eliminating the signs 
of withdrawal. They also reported that patients 
receiving buprenorphine completed the 
 
Table 1. Comparison of changes in clinical opiate withdrawal scale (COWS) and adjective rating withdrawal 
scale (ARWS) scores and craving in the two groups receiving clonidine and buprenorphine 
Variables Drug group First day Second day Third day Fifth day P Within groups Between groups
COWS score Clonidine 12.0 ± 1.7 17.0 ± 1.6 12.5 ± 1.6 3.5 ± 0.9 < 0.001 0.615 Buprenorphine 11.1 ± 1.5 15.0 ± 2.2 11.1 ± 2.6 3.1 ± 1.0 
ARWS score Clonidine 53.1 ± 4.0 54.8 ± 4.2 46.5 ± 4.7 24.1 ± 3.0 < 0.001 0.182 Buprenorphine 47.4 ± 3.4 49.1 ± 4.0 34.7 ± 6.0 17.5 ± 3.5
Craving Clonidine 89.1 ± 2.3 81.4 ± 3.5 73.3 ± 3.5 62.0 ± 3.8 < 0.001 0.870 Buprenorphine 72.1 ± 2.8 72.1 ± 2.8 82.1 ± 3.2 92.1 ± 2.6
Values are expressed as mean ± SD; COWS: Clinical opiate withdrawal scale; ARWS: Adjective rating withdrawal scale 
 
Table 2. Number of days remaining in treatment and receiving naltrexone in the two groups during a six-month 
follow-up 
Drug Group  Naltrexone consumption P Stay in treatment P 
Clonidine  30.7 ± 9.1 0.743 87.7 ± 14.9 0.301 Buprenorphine  38.4 ± 13.2 59.7 ± 19.6 
 
Table 3. Frequency distribution of naltrexone consumption in the two groups receiving buprenorphine and 
clonidine during a six-month follow-up  
Group Continued naltrexone Discontinued naltrexone Not reachable 
Clonidine 9 (43) 10 (48) 2 (9) 
Buprenorphine 9 (64) 5 (36) - 
Values are presented as number (%) 
 
Table 4. Frequency distribution of number of subjects who received maintenance treatment in the two groups 
Group Received maintenance treatment Not reachable Yes No 
Clonidine 13 (62.0) 6 (28.5) 2 (9.5) 
Buprenorphine 13 (92.8) 1 (7.2) - 
Values are presented as number (%) 
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detoxification period more effectively. 
Moreover, although there was no significant 
difference in the occurrence of side effects, it 
seemed that more patients abandoned 
treatment due to the side effects of clonidine.4 
The difference between our findings and those 
of Gowing et al. may be due to different 
number of samples, consumption of opioids 
with stronger effects, differences in 
detoxification periods during regimens, and 
different drug metabolism in subjects.1 Similar 
to Gowing et al., Nigam et al. reported the 
superiority of buprenorphine to clonidine in 
controlling the signs and symptoms of 
withdrawal from opioids.14 These 
inconsistencies suggest that in addition to the 
dose of medication, the length of detoxification 
period can also play an important role in 
treatment results. Cheskin et al. compared a 
three-day high-dose buprenorphine regimen 
with a standard five-day clonidine regimen in 
an inpatient and double-blind study on 25 men 
and women dependent on heroin. They found 
no difference in physiological and subjective 
factors of the two groups. However, clonidine 
had more effects on hypotension and 
buprenorphine eliminated the signs of 
withdrawal earlier.16 This difference with our 
study can also be due to differences in the 
effectiveness of the used drugs and the use of 
high-dose medicine regimens.  
Our study was conducted on patients 
admitted to a detoxification center. A previous 
study on four groups (outpatients and 
inpatients receiving either buprenorphine or 
clonidine for 13 days) showed that patients in 
the clonidine group had milder withdrawal 
signs, stayed in treatment longer, and obtained 
better results.24 
A comparison between three detoxification 
methods including clonidine, clonidine with 
naltrexone, and clonidine with buprenorphine 
showed treatment success rates of 65%, 81%, 
and 81%, respectively. Moreover, patients 
receiving the two combinations completed 
treatment more efficiently than those under 
clonidine alone.11 Benefits of the combination of 
buprenorphine and clonidine for opium 
detoxification have been supported by other 
research.26 
Preventing the recurrence of drug abuse is a 
crucial step following detoxification. It can be 
achieved by drug or non-drug methods, 
independent or combined. Due to the wide 
range of social workers involved in substance 
abuse and its legal consequences, studies on the 
efficacy of these methods are different in 
various communities and lack certain criteria.27 
The excessive desire for drug abuse is related to 
the euphoria caused by opioids which is 
mediated by the mu receptors. Naltrexone, an 
antagonist of the mu receptor, has been 
approved by the US FDA for treatment of 
alcohol dependence and blockade of the effects 
of opioids.5,27 Studies have reported the 
combination of buprenorphine and naltrexone 
to be associated with lower recurrence rate, 
lower tendency to use drugs, and higher 
percentage of negative urine samples.4 
In the present study, 43% of the subjects 
detoxified with clonidine and 64% of those 
detoxified with buprenorphine continued 
taking naltrexone for one month. This 
difference, which was considerable but not 
statistically significant, might have been caused 
by better family support and better personal 
skills in dealing with stress after detoxification 
with buprenorphine.28 It is noteworthy that 
subjects in both groups had stopped using 
naltrexone in the 6-month follow-up which 
shows the importance of supervised use of 
naltrexone during the follow-up period. In 
another study, 20-30% of patients remained 
under treatment with naltrexone after six 
months.29 
In the present study, 62% of patients in the 
clonidine group and 92.8% of subjects in the 
buprenorphine group received maintenance 
treatment. A survey on maintenance treatment 
after five methods of detoxification indicated 
that the highest number of individuals who 
received maintenance treatment had been 
detoxified with buprenorphine.30 However, we 
did not find statistically significant differences 
in mean days of stay in treatment between the 
two groups.  
Developing a method of opioid withdrawal 
with shorter time period and lower costs to 
help patients transfer from the state of 
dependence to the maintenance period with 
minimum loss would be absolutely beneficial. 
Many researchers including Bearn et al.,31 
Charney et al.,32 and Koyuncuoglu33 have 
confirmed the usefulness of maintenance 
treatment with naltrexone. Naltrexone has in 
fact been suggested as an alternative to 
maintenance treatment with opioid agonist 
(methadone).34 
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In this study, patients and their families 
claimed reduced amount and frequency of drug 
abuse in those who failed to maintain 
abstinence compared to conditions before 
detoxification. Vining et al.35 and Bearn et al.36 
reported similar findings. However, our success 
rates were lower than studies which included 
non-pharmacological programs such as group 
therapy, family therapy, or community-based 
treatment. This shows the advantage of these 
methods in controlling signs of opioid 
withdrawal. Therefore, the main disadvantage 
of naltrexone consumption may be the lack of a 
mechanism to induce patients to continue 
taking the drug.5 
 
Conclusion 
Although buprenorphine did not have a 
significant statistical difference with clonidine 
in controlling the symptoms of opioid 
withdrawal, patients detoxified with 
buprenorphine entered maintenance treatment 
to a greater extent. However, the recurrence 
rate was not significantly different between the 
two groups. Hence, it is suggested to choose 
one of the two methods based on each patient's 
willingness and physical conditions, health care 
costs, and physician's clinical judgment. The 
side effects should also be considered when 
selecting a drug. Future studies to maintain 
abstinence and reduce recurrence rates after 
detoxification are recommended to supervise 
and control the prescription of naltrexone more 
precisely, carry out a greater follow-up for 
urine test of morphine, and include non-
medicinal programs such as individual 
psychotherapy, behavioral therapy, cognitive 
therapy, family therapy, support groups and 
social skills training to enhance individual, 
interpersonal, psychological, and social 
capabilities of patients.  
The limitations of this study were low 
number of subjects, two groups of non-equal 
number, and lack of more accurate monitoring 
of the use of naltrexone and morphine urine 
test. More comprehensive supervision in 
further studies would reveal more precise 
results. 
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ﺮاد واﺑﺴﺘﻪ ﺑﻪ ﺗﺮﻳﺎك و ﻣﻴﺰان زداﻳﻲ اﻓ ﻣﻘﺎﻳﺴﻪ ﻛﺎراﻳﻲ ﺑﻮﭘﺮﻧﻮرﻓﻴﻦ و ﻛﻠﻮﻧﻴﺪﻳﻦ در ﺳﻢ
  ﮕﻴﺮي ﺷﺶ ﻣﺎﻫﻪﻮاد ﺑﺎ ﻣﺼﺮف ﻧﺎﻟﺘﺮﻛﺴﻮن در ﻳﻚ ﭘﻴﭘﺮﻫﻴﺰ از ﻣﺼﺮف ﻣ
  
  3ﻧﻮذر ﻧﺨﻌﻲدﻛﺘﺮ ، 2ﻣﻨﺼﻮره ﻧﺼﻴﺮﻳﺎندﻛﺘﺮ ، 1ﺣﺴﻦ ﺿﻴﺎء اﻟﺪﻳﻨﻲدﻛﺘﺮ 
  
  
  ﭼﻜﻴﺪه
ﺑﻪ اﻓﺰاﻳﺶ ﺗﻌﺪاد  زداﻳﻲ ﺑﺎ ﻋﻮارض ﻛﻤﺘﺮ در دوره ﺑﺎزﮔﻴﺮي از اﭘﻴﻮﻳﻴﺪﻫﺎ و ﭘﺎﻳﺎﻳﻲ ﺑﻴﺸﺘﺮ آن ﺑﺎ ﺗﻮﺟﻪ ﺑﻪ ﻛﺎرﮔﻴﺮي روش ﺳﻢ: ﻣﻘﺪﻣﻪ
ﭼﻨﺪاﻧﻲ  زداﻳﻲ، ﺑﻴﻤﺎر وارد درﻣﺎن ﻧﮕﻬﺪارﻧﺪه ﻧﺸﻮد، ﻣﻮﻓﻘﻴﺖ رﺳﺪ و ﭼﻨﺎن ﭼﻪ ﺑﻌﺪ از ﺳﻢ ﻣﺼﺮف ﻛﻨﻨﺪﮔﺎن ﻣﻮاد ﻣﺨﺪر ﺿﺮوري ﺑﻪ ﻧﻈﺮ ﻣﻲ
زداﻳﻲ ﺑﺎ دو روش اﺳﺘﻔﺎده از ﺑﻮﭘﺮﻧﻮرﻓﻴﻦ زﻳﺮ زﺑﺎﻧﻲ و ﻛﻠﻮﻧﻴﺪﻳﻦ  آﻣﻴﺰ ﺑﻮدن ﺳﻢ اﻳﻦ ﻣﻄﺎﻟﻌﻪ ﺑﻪ ﻣﻘﺎﻳﺴﻪ ﻣﻴﺰان ﻣﻮﻓﻘﻴﺖ. ﻧﺨﻮاﻫﺪ داﺷﺖ
  .ﮕﻴﺮي ﺷﺶ ﻣﺎﻫﻪ در ﺑﻴﻤﺎران ﺑﺎ ﻣﺼﺮف ﻧﺎﻟﺘﺮﻛﺴﻮن را ﻣﻮرد ارزﻳﺎﺑﻲ ﻗﺮار دادﭙﺲ ﻣﻴﺰان ﻋﻮد ﻣﺼﺮف ﻣﻮاد در ﻳﻚ ﭘﻴاﺧﺖ و ﺳﭘﺮد
ﺑﺮ روي  6831- 88ﻫﺎي  ﭘﺰﺷﻜﻲ ﻛﺮﻣﺎن و در ﺳﺎل ﻛﻮر ﺑﻮد ﻛﻪ در ﺑﻴﻤﺎرﺳﺘﺎن روان ﺳﻮ ﻣﻄﺎﻟﻌﻪ ﺣﺎﺿﺮ از ﻧﻮع ﻛﺎرآزﻣﺎﻳﻲ دو :ﻫﺎ روش
ﮔﻴﺮي ﺗﺼﺎدﻓﻲ در دو ﮔﺮوه درﻳﺎﻓﺖ ﻛﻨﻨﺪه  اﻳﻦ اﻓﺮاد ﺑﺎ روش ﻧﻤﻮﻧﻪ. زداﻳﻲ، اﻧﺠﺎم ﺷﺪ اﻓﺮاد واﺑﺴﺘﻪ ﺑﻪ ﺗﺮﻳﺎك ﺟﺴﺘﺠﻮي درﻣﺎن ﺳﻢ
زداﻳﻲ ﺑﺎ ﻣﺼﺮف ﻧﺎﻟﺘﺮﻛﺴﻮن در ﭘﺎﻳﺎن دوره، ارزﻳﺎﺑﻲ و ﺳﭙﺲ ﺑﻴﻤﺎران ﺑﺎ ﻣﺼﺮف  زداﻳﻲ ﺷﺪﻧﺪ و ﻣﻮﻓﻘﻴﺖ ﺳﻢ ﻛﻠﻮﻧﻴﺪﻳﻦ و ﺑﻮﭘﺮﻧﻮرﻓﻴﻦ ﺳﻢ
  .ﮕﻴﺮي ﺷﺪﻧﺪﺎﻟﺘﺮﻛﺴﻮن و ﻋﺪم ﻋﻮد ﻣﺼﺮف ﻣﻮاد ﭘﻴﻪ ﻣﺼﺮف ﻧﻣﺎه از ﻧﻈﺮ اداﻣ 6ﮔﺮم ﻧﺎﻟﺘﺮﻛﺴﻮن ﺗﺮﺧﻴﺺ ﺷﺪه و ﺑﺮاي  ﻣﻴﻠﻲ 52روزاﻧﻪ 
در ﮔﺮوه . زداﻳﻲ ﺑﺎ ﻣﺼﺮف ﻧﺎﻟﺘﺮﻛﺴﻮن در ﻫﻤﻪ اﻓﺮاد ﺗﺄﻳﻴﺪ ﮔﺮدﻳﺪ آﻣﻴﺰ ﺑﻮدن ﺳﻢ ﻧﻔﺮ وارد ﻣﻄﺎﻟﻌﻪ ﺷﺪﻧﺪ ﻛﻪ ﻣﻮﻓﻘﻴﺖ 53در ﻣﺠﻤﻮع،  :ﻫﺎ ﻳﺎﻓﺘﻪ
   (elacs lawardhtiw etaipo lacinilC) SWOC ﻣﻴﺎﻧﮕﻴﻦ( درﺻﺪ 4/8)ﻳﻚ ﻧﻔﺮ ، (ﻧﻔﺮ 12= ﺗﻌﺪاد )درﻳﺎﻓﺖ ﻛﻨﻨﺪه ﻛﻠﻮﻧﻴﺪﻳﻦ 
ﭘﻨﺠﻢ  در روز را 21ﺑﻴﺶ از  SWOCﭘﻨﺠﻢ ﻧﺸﺎن داد و در ﮔﺮوه درﻳﺎﻓﺖ ﻛﻨﻨﺪه ﺑﻮﭘﺮﻧﻮرﻓﻴﻦ، ﻫﻴﭻ ﻛﺪام ﻣﻴﺎﻧﮕﻴﻦ  روزرا در  21ﺑﻴﺸﺘﺮ از 
زداﻳﻲ  ﻫﺎي ذﻫﻨﻲ ﺗﺮك و ﻣﻴﻞ ﺑﻪ ﻣﺼﺮف ﻣﻮاد در ﻫﺮ دو ﮔﺮوه ﻃﻲ دوره ﺳﻢ ﻣﻴﺎﻧﮕﻴﻦ ﻋﻼﻳﻢ ﻋﻴﻨﻲ و ﻧﺸﺎﻧﻪ .(P > 0/50)ﻧﺪاﺷﺘﻨﺪ 
درﺻﺪ  34. (P > 0/50)دار ﻧﺒﻮد  ﻣﻘﺎﻳﺴﻪ اﻳﻦ ﻣﺘﻐﻴﺮﻫﺎ ﺑﻴﻦ دو ﮔﺮوه از ﻧﻈﺮ آﻣﺎري ﻣﻌﻨﻲ، اﻣﺎ (P < 0/10)ﻫﺶ ﭼﺸﻤﮕﻴﺮي داﺷﺖ ﻛﺎ
زداﻳﻲ ﺷﺪه ﺑﺎ ﺑﻮﭘﺮﻧﻮرﻓﻴﻦ، ﻣﺼﺮف ﻧﺎﻟﺘﺮﻛﺴﻮن را ﺑﻪ ﻃﻮر ﻣﺘﻮﺳﻂ ﺑﺮاي ﻳﻚ  اﻓﺮاد ﺳﻢ از درﺻﺪ 46زداﻳﻲ ﺷﺪه ﺑﺎ ﻛﻠﻮﻧﻴﺪﻳﻦ و  اﻓﺮاد ﺳﻢاز 
زداﻳﻲ ﺷﺪه ﺑﺎ ﺑﻮﭘﺮﻧﻮرﻓﻴﻦ وارد درﻣﺎن ﻧﮕﻬﺪارﻧﺪه  درﺻﺪ اﻓﺮاد ﺳﻢ 29/8زداﻳﻲ ﺷﺪه ﺑﺎ ﻛﻠﻮﻧﻴﺪﻳﻦ و  اﻓﺮاد ﺳﻢدرﺻﺪ  26ﻣﺎه اداﻣﻪ دادﻧﺪ و 
  (.P > 0/50) داري را ﻧﺸﺎن ﻧﺪاد ﺷﺪﻧﺪ، اﻣﺎ ﻣﻴﺎﻧﮕﻴﻦ روزﻫﺎي ﺑﺎﻗﻲ ﻣﺎﻧﺪن در درﻣﺎن در دو ﮔﺮوه از ﻧﻈﺮ آﻣﺎري ﺗﻔﺎوت ﻣﻌﻨﻲ
و درﺻﺪ ﺑﻴﺸﺘﺮي از اﻓﺮاد  ﺑﻮدل ﻣﺆﺛﺮ ﻧﺸﺎﻧﮕﺎن ﻣﺤﺮوﻣﻴﺖ از ﻣﻮاد ﺗﺄﺛﻴﺮﮔﺬار ﺑﻮﭘﺮﻧﻮرﻓﻴﻦ ﻧﻴﺰ ﻣﺎﻧﻨﺪ ﻛﻠﻮﻧﻴﺪﻳﻦ در ﻛﻨﺘﺮ :ﮔﻴﺮي ﻧﺘﻴﺠﻪ
  .زداﻳﻲ ﺷﺪه ﺑﺎ ﺑﻮﭘﺮﻧﻮرﻓﻴﻦ وارد درﻣﺎن ﻧﮕﻬﺪارﻧﺪه ﺷﺪﻧﺪ، وﻟﻲ ﻣﻴﺰان ﻋﻮد ﻣﺼﺮف ﻣﻮاد در دو روش ﺗﻔﺎوت ﭼﻨﺪاﻧﻲ ﻧﺪاﺷﺖ ﺳﻢ
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